These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26292715)

  • 1. Ambivalence about supervised injection facilities among community stakeholders.
    Strike C; Watson TM; Kolla G; Penn R; Bayoumi AM
    Harm Reduct J; 2015 Aug; 12():26. PubMed ID: 26292715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supervised injection facilities in Canada: past, present, and future.
    Kerr T; Mitra S; Kennedy MC; McNeil R
    Harm Reduct J; 2017 May; 14(1):28. PubMed ID: 28521829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Support of supervised injection facilities by emergency physicians in Canada.
    Katz N; Leonard L; Wiesenfeld L; Perry JJ; Thiruganasambandamoorthy V; Calder L
    Int J Drug Policy; 2017 Nov; 49():26-31. PubMed ID: 28886562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility.
    Kerr T; Small W; Moore D; Wood E
    Int J Drug Policy; 2007 Jan; 18(1):37-45. PubMed ID: 17689342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prospect of implementing a Safer Injection Facility in San Francisco: perspectives of community stakeholders.
    Wenger LD; Arreola SG; Kral AH
    Int J Drug Policy; 2011 May; 22(3):239-41. PubMed ID: 21334185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of on-site detoxification services co-located with a supervised injection facility.
    Gaddis A; Kennedy MC; Nosova E; Milloy MJ; Hayashi K; Wood E; Kerr T
    J Subst Abuse Treat; 2017 Nov; 82():1-6. PubMed ID: 29021106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing support for supervised injection services among community stakeholders in London, Canada.
    Bardwell G; Scheim A; Mitra S; Kerr T
    Int J Drug Policy; 2017 Oct; 48():27-33. PubMed ID: 28666204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. My place, your place, or a safer place: the intention among Montréal injecting drug users to use supervised injecting facilities.
    Green TC; Hankins CA; Palmer D; Boivin JF; Platt R
    Can J Public Health; 2004; 95(2):110-4. PubMed ID: 15074900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia.
    Salmon AM; van Beek I; Amin J; Kaldor J; Maher L
    Addiction; 2010 Apr; 105(4):676-83. PubMed ID: 20148794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users.
    Wood E; Kerr T; Spittal PM; Li K; Small W; Tyndall MW; Hogg RS; O'Shaughnessy MV; Schechter MT
    J Acquir Immune Defic Syndr; 2003 Jan; 32(1):2-8. PubMed ID: 12514408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on supervised injection facilities among service industry employees in New York City: A qualitative exploration.
    Wolfson-Stofko B; Elliott L; Bennett AS; Curtis R; Gwadz M
    Int J Drug Policy; 2018 Dec; 62():67-73. PubMed ID: 30359875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing public support for supervised injection facilities in Ontario, Canada.
    Strike C; Jairam JA; Kolla G; Millson P; Shepherd S; Fischer B; Watson TM; Bayoumi AM
    Addiction; 2014 Jun; 109(6):946-53. PubMed ID: 24520984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding supervised injection facilities across Canada: lessons from the Vancouver experience.
    Young S; Fairbairn N
    Can J Public Health; 2018 Apr; 109(2):227-230. PubMed ID: 29981039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada.
    Cruz MF; Patra J; Fischer B; Rehm J; Kalousek K
    Int J Drug Policy; 2007 Jan; 18(1):54-61. PubMed ID: 17689344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The willingness of people who inject drugs in Boston to use a supervised injection facility.
    León C; Cardoso L; Mackin S; Bock B; Gaeta JM
    Subst Abus; 2018 Jan; 39(1):95-101. PubMed ID: 28799847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do supervised injecting facilities attract higher-risk injection drug users?
    Wood E; Tyndall MW; Li K; Lloyd-Smith E; Small W; Montaner JS; Kerr T
    Am J Prev Med; 2005 Aug; 29(2):126-30. PubMed ID: 16005809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willingness to access an in-hospital supervised injection facility among hospitalized people who use illicit drugs.
    Ti L; Buxton J; Harrison S; Dobrer S; Montaner J; Wood E; Kerr T
    J Hosp Med; 2015 May; 10(5):301-6. PubMed ID: 25754871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of public support toward federal funding for harm reduction strategies.
    Kulesza M; Teachman BA; Werntz AJ; Gasser ML; Lindgren KP
    Subst Abuse Treat Prev Policy; 2015 Jun; 10():25. PubMed ID: 26122408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.